Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PIK3CA mut PTEN loss||breast cancer||sensitive||Alpelisib + AZD6482||Preclinical - Pdx||Actionable||In a preclinical study, AZD6482 and Alpelisib (BYL719) combination treatment inhibited Akt signaling and growth in a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss (Cancer Res October 1, 2014 74; LB-327).||detail...|
|PIK3CA mut PTEN loss||breast cancer||resistant||Alpelisib||Case Reports/Case Series||Actionable||In a clinical case study, a breast cancer patient harboring a PIK3CA mutation developed resistance to Alpelisib (BYL719) treatment and progressive disease after initial response, accompanied by a loss of PTEN, and the corrresponding patient-derived xenograft model demonstrated resistance to Alpelisib (BYL719)-induced inhibition of tumor growth (PMID: 25409150).||detail... 25409150|
|PIK3CA mut PTEN loss||breast cancer||sensitive||Buparlisib||Preclinical - Pdx||Actionable||In a preclinical study, Buparlisib (BKM120) inhibited Akt signaling and growth in a PDX model of breast cancer cells harboring a PIK3CA mutation and PTEN loss ( Cancer Res October 1, 2014 74; LB-327 ).||detail...|
|PIK3CA mut PTEN loss||prostate cancer||sensitive||PKI-179||Preclinical - Cell culture||Actionable||In a preclinical study, PKI-179 inhibited growth of prostate cancer cells harboring PIK3CA mutations and PTEN loss in culture (PMID: 20797855).||20797855|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|